Rusfertide peptide

Rusfertide peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

{Asp(N-(3-methyl-1-oxobutyl))}-THFPCI-{Lys(γGlu-C16 acid)}-FEPRSKGCK-NH2 (disulfide bridge: Cys6-Cys16)

{Asp(N-(3-methyl-1-oxobutyl))}-Thr-His-Phe-Pro-Cys-Ile-{Lys(γGlu-C16 acid)}-Phe-Glu-Pro-Arg-Ser-Lys-Gly-Cys-Lys-NH2 (disulfide bridge: Cys6-Cys16)

17

95.46%

C₁₁₄H₁₈₁N₂₇O₂₈S₂

2442

1628323-80-7

155884410

Synthetic

Powder

Rusfertide(PTG-300) is a peptide mimetic of natural hepcidin, which targets the major iron transporter, ferroportin, and causes its internalization and subsequent degradation. This leads to reductions in serum iron and transferrin saturation (TSAT) due to reduced ferroportin expression on cells that store or recycle iron. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Roopa Taranath, Gregory Bourne, Li Zhao, Brian Frederick, Chelsea King, David Liu, Regulation of Iron Homeostasis By PTG-300 Improves Disease Parameters in Mouse Models for Beta-Thalassemia and Hereditary Hemochromatosis, Blood, Volume 134, Supplement 1, 2019, Page 3540, ISSN 0006-4971, https://doi.org/10.1182/blood-2019-129309.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.